You are here

AstraZeneca says it prioritizes US for RSV drug amid surge in cases

Primary tabs

Error message

You are not authorized to post comments.

Mon, 2023-11-13 11:33 — mike kraft

AstraZeneca prioritizes US for RSV drug amid surge in cases AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply. Patrick Wingrove,Maggie Fick Reuters

Country / Region Tags:

General Topic Tags:

Disease Prevention

Problem, Solution, SitRep, or ?:

Situation Report

Groups this Group Post belongs to:

- Private group -

Log in or register to post comments